# Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

> **NCT00412061** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 429 (actual)

## Conditions studied

- Carcinoid Tumor
- Malignant Carcinoid Syndrome

## Interventions

- **DRUG:** Octreotide
- **DRUG:** Placebo
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00412061
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-04
- **Final completion:** 2013-06
- **Target enrollment:** 429 (ACTUAL)
- **Last updated:** 2014-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412061, "Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00412061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*